2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational

Program: Oral Abstract Session
Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 343-345
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Cell Expansion, Profiling, Treatment Considerations, Biological Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Microbiome, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Research, AML, Translational Research, Study Population, Human, Animal Model
PAPER

128 Comprehensive characterization of a high-risk mast cell-like leukemia subset in t(8;21) AML and development of its IL5RA-targeted CAR-T therapy

Yu Liu, Fan Ding2, Qianqian Huang3, Manling Chen4, Yingxi Xu, PhD5, Runxia Gu, MD6, Min Wang, PhD7, Wenbing Liu8, Shaowei Qiu, MD9, Jianxiang Wang Sr, MD, PhD10
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China

The t(8;21)(q22;q22) translocation is among the most frequent chromosomal abnormalities in acute myeloid leukemia (AML). Although most patients achieve initial remission after induction chemotherapy, approximately 30%-40% ultimately relapse, and long-term outcomes remain dismal, largely due to the difficulty in detecting and eradicating relapse-initiating leukemic clones at an early stage.

To address the clinical need, we first dissected the intratumoral heterogeneity of t(8;21) AML by single-cell RNA sequencing of bone marrow samples from 9 patients before and after chemotherapy, alongside healthy donor controls. We extracted malignant cells using previously described hematopoietic stem and progenitor cell (HSPC) scores and AML1-ETO scores. Further unsupervised clustering identified five distinct subsets: DMP-like, HSPC-1-like, HSPC-2-like, Cycling_HSPC-like, and mast cell-like leukemic cells. The mast cell-like subset was enriched for mast cell signatures and canonical pathways. These observations were consistently validated in scRNA-seq datasets from multiple AML1-ETO-driven mouse models, collectively confirming the existence of a mast cell-like leukemia subset in t(8;21) AML. Moreover, this subset displayed higher stemness scores, a more primitive and quiescent cellular status, and an earlier differentiation block, rendering it more likely to persist after chemotherapy and to serve as a reservoir for minimal residual disease.

To functionally characterize the phenotype of this subset, we isolated mast cell-like and control leukemic cells from the same patients and cultured them with or without daunorubicin. The mast cell-like leukemic cells demonstrated enhanced proliferative capacity and superior resistance to apoptosis. These features were further recapitulated in AML1-ETO mouse models, in which the mast cell-like leukemia cells exhibited a higher proportion of cells arrested in G0 phase and stronger self-renewal capacity in colony formation assays. Together, these functional assays underscored the more aggressive and therapy-refractory characteristics of the mast cell-like leukemia subset.

Having established its aggressive phenotype, we next sought to determine whether the mast cell-like profile is specific to t(8;21) AML. We therefore performed integrated multi-omics profiling (transcriptomics, proteomics, and metabolomics) on CD34? leukemic cells from t(8;21) AML patients versus non-t(8;21) primitive AML cases, as well as on c-Kit? cells from AML1-ETO mice versus wild-type controls. Strikingly, mast cell-related pathways (e.g., FcεRI signaling) and mast cell-associated genes (e.g., CPA3, TPSD1 and TPSAB1) were consistently and significantly upregulated in both human and murine t(8;21) AML cells compared with their respective controls. These findings establish this mast cell-like subset as a t(8;21) AML-specific pathogenic population and underscore the need for its early elimination to achieve deeper remission.

To translate these biological insights into therapeutic strategies, we sought to identify gene signatures suitable for tracking and targeting this subset. We identified IL5RA as a specific cell-surface marker for the mast cell-like leukemia subset and validated its utility for tracking the AML1-ETO fusion transcript via probe-based digital PCR. Furthermore, we engineered a second-generation CAR construct using human IL-5 as the ligand-based recognition domain, coupled with 4-1BB and CD3ζ signaling domains. The resulting IL5RA CAR-T cells exerted potent, specific cytotoxicity against IL5RA-positive cells both in vitro and in vivo, efficiently eliminated primary t(8;21) AML blasts, and exhibited no detectable off-target toxicity toward normal CD34? HSPCs. These preclinical data support IL5RA CAR-T as a promising strategy to eradicate relapse-prone clones in t(8;21) AML.

In summary, our study provides a comprehensive multi-omics and single-cell characterization of a previously underappreciated mast cell-like leukemia subset in t(8;21) AML, functionally validates its more aggressive, therapy-refractory features, identifies IL5RA as its specific marker, and demonstrates the efficacy of IL5RA-targeted CAR-T therapy for eradicating these relapse-prone leukemic clones. These findings advance our understanding of the cellular heterogeneity underlying treatment resistance in t(8;21) AML and establish a robust foundation for developing novel immunotherapeutic strategies to improve long-term outcomes for these patients.

Yu Liu: No relevant conflicts of interest to declare.